JP2010202664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010202664A5 JP2010202664A5 JP2010130425A JP2010130425A JP2010202664A5 JP 2010202664 A5 JP2010202664 A5 JP 2010202664A5 JP 2010130425 A JP2010130425 A JP 2010130425A JP 2010130425 A JP2010130425 A JP 2010130425A JP 2010202664 A5 JP2010202664 A5 JP 2010202664A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- seq
- amino acid
- patient
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010054218 Factor VIII Proteins 0.000 claims 19
- 229960000301 Factor VIII Drugs 0.000 claims 19
- 102000001690 Factor VIII Human genes 0.000 claims 19
- 102000004965 antibodies Human genes 0.000 claims 8
- 108090001123 antibodies Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 102100000368 F8 Human genes 0.000 claims 2
- 101700070229 F8 Proteins 0.000 claims 2
- 230000036499 Half live Effects 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 206010047715 Von Willebrand's disease Diseases 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 201000005114 blood coagulation disease Diseases 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 230000004059 degradation Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 201000003542 factor VIII deficiency Diseases 0.000 claims 2
- 230000003480 fibrinolytic Effects 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000002537 thrombolytic Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37635102P | 2002-04-29 | 2002-04-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501452A Division JP2005535588A (ja) | 2002-04-29 | 2003-04-28 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010202664A JP2010202664A (ja) | 2010-09-16 |
| JP2010202664A5 true JP2010202664A5 (ko) | 2011-07-21 |
Family
ID=29401334
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501452A Pending JP2005535588A (ja) | 2002-04-29 | 2003-04-28 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
| JP2010130425A Pending JP2010202664A (ja) | 2002-04-29 | 2010-06-07 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501452A Pending JP2005535588A (ja) | 2002-04-29 | 2003-04-28 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8586538B2 (ko) |
| EP (1) | EP1497330B1 (ko) |
| JP (2) | JP2005535588A (ko) |
| AT (1) | ATE463514T1 (ko) |
| AU (1) | AU2003227687B2 (ko) |
| CA (1) | CA2484155C (ko) |
| DE (1) | DE60332011D1 (ko) |
| DK (1) | DK1497330T3 (ko) |
| ES (1) | ES2343681T3 (ko) |
| WO (1) | WO2003093313A2 (ko) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004003144A2 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| EP1454632A1 (en) * | 2003-02-07 | 2004-09-08 | Aventis Behring GmbH, Intellectual Property/Legal | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006003183A1 (de) * | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptide zur blockierung von fviii-inhibitoren |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| JP2009274958A (ja) | 2006-08-31 | 2009-11-26 | Nara Prefecture | 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体 |
| KR101542752B1 (ko) | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
| US20110286988A1 (en) * | 2008-06-04 | 2011-11-24 | Bayer Healthcare Llc | FVIII Muteins for Treatment of Von Willebrand Disease |
| KR101507718B1 (ko) | 2008-06-24 | 2015-04-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체 |
| JP5394864B2 (ja) * | 2009-09-10 | 2014-01-22 | アスモ株式会社 | モータ |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| CN104788557A (zh) | 2010-09-15 | 2015-07-22 | 诺沃—诺迪斯克有限公司 | 具有减少的细胞摄取的因子viii变体 |
| WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| CA2953593C (en) | 2014-07-02 | 2023-09-26 | Csl Limited | Modified von willebrand factor |
| CA2978374A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| DK3297656T3 (da) | 2015-05-22 | 2020-03-09 | CSL Behring Lengnau AG | Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili |
| RU2017145002A (ru) | 2015-05-22 | 2019-06-24 | Цсл Беринг Ленгнау Аг | Способы получения модифицированного фактора фон виллебранда |
| JP6851381B6 (ja) | 2016-01-07 | 2021-04-21 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 変異切断型フォンウィルブランド因子 |
| CN108779165B (zh) | 2016-01-07 | 2022-12-02 | 康诺贝林伦瑙有限公司 | 突变的冯·维勒布兰德因子 |
| JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
| TW201828975A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Ｃｓｌ貝林重組技能公司 | 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713303B2 (en) * | 1995-06-12 | 1999-11-25 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation |
| US7364735B1 (en) * | 1998-05-08 | 2008-04-29 | Stichting Sanquin Bloedvoorziening | Method for diagnosis and treatment of haemophilia A patients with an inhibitor |
| AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
| DK1129186T4 (da) * | 1998-11-10 | 2017-02-06 | Stichting Sanquin Bloedvoorziening | Et faktor VIII-polypeptid med faktor VIII:C-aktivitet |
-
2003
- 2003-04-28 US US10/512,907 patent/US8586538B2/en active Active
- 2003-04-28 WO PCT/EP2003/004425 patent/WO2003093313A2/en active Application Filing
- 2003-04-28 EP EP03725109A patent/EP1497330B1/en not_active Expired - Lifetime
- 2003-04-28 AT AT03725109T patent/ATE463514T1/de active
- 2003-04-28 JP JP2004501452A patent/JP2005535588A/ja active Pending
- 2003-04-28 DE DE60332011T patent/DE60332011D1/de not_active Expired - Lifetime
- 2003-04-28 AU AU2003227687A patent/AU2003227687B2/en not_active Ceased
- 2003-04-28 DK DK03725109.7T patent/DK1497330T3/da active
- 2003-04-28 ES ES03725109T patent/ES2343681T3/es not_active Expired - Lifetime
- 2003-04-28 CA CA2484155A patent/CA2484155C/en not_active Expired - Lifetime
-
2010
- 2010-06-07 JP JP2010130425A patent/JP2010202664A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010202664A5 (ko) | ||
| JP2018511327A5 (ko) | ||
| JP2019196365A5 (ko) | ||
| RU2534564C3 (ru) | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii | |
| JP2017160222A5 (ko) | ||
| JP2010534486A5 (ko) | ||
| JP2018522563A5 (ko) | ||
| JP2012136541A5 (ko) | ||
| JP2008508859A5 (ko) | ||
| JP2009017881A5 (ko) | ||
| JP2018510132A5 (ko) | ||
| JP2008535800A5 (ko) | ||
| JP2008538564A5 (ko) | ||
| JP2010505444A5 (ko) | ||
| JP2013127002A5 (ko) | ||
| JP2005535588A5 (ko) | ||
| JP2013520405A5 (ko) | ||
| RU2015120804A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| JP2013503110A5 (ko) | ||
| JP2013510169A5 (ko) | ||
| MY192113A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| JP2012513193A5 (ko) | ||
| JP2015517489A5 (ko) | ||
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| JP2010530238A5 (ko) |